PMID- 36063222
OWN - NLM
STAT- MEDLINE
DCOM- 20230719
LR  - 20230719
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 149
IP  - 8
DP  - 2023 Jul
TI  - Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with 
      advanced pathological features in laryngeal squamous cell carcinoma.
PG  - 4253-4267
LID - 10.1007/s00432-022-04336-z [doi]
AB  - INTRODUCTION: Recent developments in genomic sequencing have led to the 
      identification of somatic mutations in isocitrate dehydrogenase 1 (IDH1) in 
      various malignancies. IDH1 R132H is the most common mutation of IDH1, which 
      affects codon 132 and results in the conversion of amino acid residue arginine 
      (R) to histidine (H). This study is designed to evaluate the association between 
      the expression of IDH1 R132H and clinicopathological characteristics in laryngeal 
      squamous cell carcinoma (LSCC). METHODS: The expression pattern and clinical 
      significance of IDH1 R132H were investigated in tissue microarrays (TMAs) of 50 
      LSCC tumors as well as adjacent normal tissues using immunohistochemistry. Then 
      the exons of the 12 tumor samples with negative/weak positive staining were 
      sequenced by applying polymerase chain reaction (PCR). RESULTS: The results 
      demonstrated that the cytoplasmic expression of IDH1 R132H was downregulated in 
      tumor cells compared to adjacent normal tissues. A statistically significant 
      association was found between a low level of cytoplasmic expression of IDH1 R132H 
      protein and an increase in histological grade (p < 0.001), perineural invasion 
      (p = 0.019), and lymph node involvement (p < 0.001). The exon4 sequencing results 
      showed that only one sample was positive for IDH1 R132H mutation. IDH1 R132H 
      expression was observed in 39 (78.0%) LSCC samples. CONCLUSION: These findings 
      indicate that low cytoplasmic expression of IDH1 R132H may have clinical 
      significance in LSCC patients and is associated with more aggressive tumor 
      behavior and progression of the disease, which can help improve potential 
      treatment in patients with LSCC. Further investigations are needed to understand 
      the biological function of IDH1 R132H and larger sample size to confirm our 
      findings.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Shayanfar, Nasrin
AU  - Shayanfar N
AD  - Department of Pathology, Rasoul Akram Hospital, Iran University of Medical 
      Sciences, Tehran, Iran.
FAU - Zare-Mirzaie, Ali
AU  - Zare-Mirzaie A
AD  - Department of Pathology, School of Medicine, Iran University of Medical Sciences, 
      Tehran, Iran.
FAU - Mohammadpour, Mahsa
AU  - Mohammadpour M
AD  - Department of Medical School, Tehran University of Medical Sciences, Tehran, 
      Iran.
FAU - Jafari, Ensieh
AU  - Jafari E
AD  - Department of Biology, Faculty of Basic Science, Noor Danesh University, Isfahan, 
      Iran.
FAU - Mehrtash, Amirhosein
AU  - Mehrtash A
AD  - Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute 
      of Iran, Tehran, Iran.
FAU - Emtiazi, Nikoo
AU  - Emtiazi N
AD  - Department of Pathology, School of Medicine, Iran University of Medical Sciences, 
      Tehran, Iran. Nikooemtiazi9@gmail.com.
FAU - Tajik, Fatemeh
AU  - Tajik F
AD  - Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran. 
      efateme_tajik@yahoo.com.
LA  - eng
GR  - Grant Number# 19921/Iran University of Medical Sciences/
PT  - Journal Article
DEP - 20220905
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
RN  - EC 1.1.1.42. (IDH1 protein, human)
SB  - IM
MH  - Humans
MH  - *Glioma/pathology
MH  - Isocitrate Dehydrogenase/genetics/metabolism
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Mutation
MH  - *Brain Neoplasms/pathology
MH  - *Head and Neck Neoplasms
OTO - NOTNLM
OT  - Immunohistochemistry (IHC)
OT  - Isocitrate dehydrogenase 1 (IDH1)
OT  - Laryngeal squamous cell carcinoma (LSCC)
OT  - Polymerase chain reaction (PCR)
OT  - Tissue microarray (TMA)
EDAT- 2022/09/06 06:00
MHDA- 2023/07/19 06:43
CRDT- 2022/09/05 11:15
PHST- 2022/07/22 00:00 [received]
PHST- 2022/08/26 00:00 [accepted]
PHST- 2023/07/19 06:43 [medline]
PHST- 2022/09/06 06:00 [pubmed]
PHST- 2022/09/05 11:15 [entrez]
AID - 10.1007/s00432-022-04336-z [pii]
AID - 10.1007/s00432-022-04336-z [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2023 Jul;149(8):4253-4267. doi: 
      10.1007/s00432-022-04336-z. Epub 2022 Sep 5.